中低收入国家孕妇百日咳免疫的成本效果:经验教训综述
本综述汇总了一个由多国团队开展、比尔及梅琳达·盖茨基金会资助的研究项目,该项目构建静态与动态传播两类模拟模型,评估中低收入国家孕妇免疫预防婴儿百日咳的成本效果。模型以巴西百日咳疾病负担数据为基础并调整关键参数代表其他中低收入国家,结果显示婴儿全细胞百日咳疫苗覆盖率是孕妇免疫成本效果的关键决定因素。
要点
- 婴儿wP疫苗覆盖率低于90-95%阈值时,孕妇百日咳免疫具成本效果甚至可节约成本。
- 婴儿wP疫苗覆盖率维持在该阈值范围或以上的国家,孕妇免疫非常昂贵。
- 动态传播模型对更准确估计成本效果必不可少,静态模型可用于初步探索。
核心结论
- 婴儿全细胞百日咳疫苗覆盖率是孕妇百日咳免疫成本效果的关键决定因素。
- 婴儿wP覆盖率低于90-95%阈值时,孕妇免疫具成本效果甚至可节约成本;覆盖率在该阈值范围或以上时非常昂贵。
- 动态传播模型对更准确估计成本效果必不可少,静态模型可用于初步探索。
研究设计与样本
- 本综述汇总一个研究项目,该项目构建静态与动态传播两类模拟模型评估中低收入国家孕妇免疫预防婴儿百日咳的成本效果。
- 研究由多国研究团队开展,比尔及梅琳达·盖茨基金会资助。
- 模型使用巴西百日咳疾病负担数据构建,假设疾病过程跨国相似,并调整关键参数代表其他中低收入国家。
主要发现
- 婴儿wP疫苗覆盖率低于90-95%阈值时,孕妇免疫具成本效果甚至可节约成本。
- 婴儿wP疫苗覆盖率维持在该阈值范围或以上的国家,孕妇免疫非常昂贵。
- 静态模型可用于初步探索干预成本效果,动态传播模型对更准确估计必不可少。
关键数值与推荐
- 婴儿wP疫苗覆盖率阈值:90-95%。
临床怎么用
- 制定孕妇百日咳免疫政策时,应优先评估当地婴儿wP疫苗覆盖率是否低于90-95%阈值。
- 在婴儿wP覆盖率低于阈值的地区,孕妇免疫可作为具成本效果甚至节约成本的公共卫生投资。
- 成本效果评估宜采用动态传播模型以获得更准确估计。
局限性
- 多数中低收入国家缺乏良好数据,模型基于巴西数据并假设疾病过程跨国相似。
- 需开发中低收入国家新生儿百日咳死亡负担与婴儿疫苗覆盖率的更好数据。
- 需开发当前可用百日咳疫苗免疫持续时间的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This issue of Vaccine is devoted to papers from a research project that developed two types of simulation models, static and dynamic transmission, to evaluate the cost-effectiveness of maternal immunization to prevent pertussis in infants in low- and middle-income countries (LMICs). The research was conducted by a multinational team of investigators and funded by the Bill & Melinda Gates Foundation to gain an understanding of when and where maternal immunization might be a good public health investment for LMICs. Here we review the project's central lessons for vaccine policy and research. Models require a lot of data. As most LMICs lack good data, the models were built using pertussis disease burden data from Brazil, a middle-income country with three long-established, independent information systems (disease surveillance, hospitalization, and mortality), on the hypothesis that the disease process is similar across countries. Values for key parameters, particularly infant mortality, infant vaccine coverage, and costs of vaccination and treatment, were then varied to represent other LMICs. The results show that coverage levels of infant whole cell pertussis (wP) vaccine are key to the cost-effectiveness of maternal pertussis immunization. In settings where infant wP coverage is below the threshold thought necessary to eliminate pertussis in the population, 90-95%, maternal immunization is cost-effective, even cost-saving. By contrast, it is very expensive in countries capable of maintaining infant vaccination in or above the threshold range. The research also suggests that, while static models may serve to explore an intervention's cost-effectiveness initially, dynamic transmission models are essential for more accurate estimates. These findings can help guide policies toward maternal pertussis immunization, but also show that developing better data on neonatal pertussis mortality burden and infant vaccine coverage in LMICs, and on the duration of immunity of currently available pertussis vaccines, are key priorities to support better vaccine policy.
引用
- Russell LB, Sobanjo-Ter Meulen A, Toscano CM, et al. Evaluating the cost-effectiveness of maternal pertussis immunization in low- and middle-income countries: A review of lessons learnt. Vaccine. 2021. PMID: 33303179. doi:10.1016/j.vaccine.2020.10.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。